7618 pharmaceutical companies were named! If you don't do it again, the winning product will be removed from the network...

Pharmaceutical Network February 8 - Zhejiang Pharmaceutical Procurement Center recently issued a notice, named 7618 enterprises, urging the pharmaceutical enterprises as soon as possible to submit the price and marketing behavior of the letter of credit.
the relevant enterprises to submit a written commitment as soon as possible by February 28 by logging on to the pharmaceutical procurement platform in Zhejiang Province.
the notice, which was relaxed until February 28, is not the first time that the Zhejiang Pharmaceutical Procurement Center has issued a letter on the compliance commitments of pharmaceutical companies.
combing through the multiple notice announcements issued by the Centre, it is clear that a clear timeline is clear: the Zhejiang Pharmaceutical Price and Recruitment Credit Evaluation System (Trial) was issued at the end of December last year (hereinafter referred to as the "Trial System"), and in January this year, on the price and recruitment of medicines Credit evaluation credit commitment letter to submit the relevant work of the consultation posted answers, and according to the actual work needs of epidemic prevention and control developed a non-digital certificate user "online material declaration" module to open the online submission of credit commitment, and then directly named 7618 pharmaceutical enterprises.
first do not mention the details of the specific documents, just from the Zhejiang Pharmaceutical Procurement Center's official website on the front page of a slip-up notice announcement, you can also see the attitude of this move.
In fact, Zhejiang issued at that time in the "trial system" has been clearly identified in the pharmaceutical price and the list of matters of mis-trust, information collection to take a combination of enterprise reports and platform records to grasp the information of the pharmaceutical enterprises, according to the court judgment or administrative punishment of the facts of the case to determine the level of disrelimony, take a graded warning, alert risk, limit or suspend the bid hanging network, public disclosure of the loss of trust information and other disposal measures, as well as encourage enterprises to take effective measures to repair credit.
, it is also proposed that "for pharmaceutical enterprises that have not submitted a commitment, the provincial pharmaceutical procurement center will refuse to register, bid for, or otherly sell medicines or medical supplies to medical institutions."
In subsequently, in the answer to questions, it was also made clear that the main body of the credit commitment and the report of the misinreinment information is all pharmaceutical and medical supplies-related enterprises online on the pharmaceutical procurement platform of Zhejiang Province, including drug production license holders, pharmaceutical and medical supplies production enterprises, distribution enterprises with the production enterprises have a principal-agent relationship, and distribution enterprises.
This latest notice, in addition to listing 7,618 pharmaceutical companies, Zhejiang Pharmaceutical Procurement Center has also made clear the rejection of the commitment of the treatment plan: enterprises that have not submitted a written commitment, from April 1, 2021, will no longer accept their new tenders or online applications;
Future or construction source information sharing mechanism industry insiders pointed out that Zhejiang Province Pharmaceutical Procurement Center this time directly named, or with the State Health Insurance Administration office issued earlier "on the accelerated implementation of pharmaceutical prices and credit evaluation system notice" (hereinafter referred to as "Notice").
The Notice stresses that keeping promises is the main basis for implementing credit ratings and taking disposal measures, and that provincial health insurance bureaus and centralized purchasing agencies should make this a top priority at this stage of their work, set phased goals and grasp them.
"Notice" also gives clear indicators: by the end of February 2021, the proportion of written commitments submitted by bidding enterprises to reach more than 80%, by the end of March 2021, to reach more than 95%.
In addition, the National Health Insurance Administration also reiterated that the provinces should effectively deal with the refusal of commitments: for those who have not submitted written commitments, from 1 April 2021, the provincial centralized procurement agencies will no longer accept their new tenders or applications for the network;
, documents issued in several provinces, like across Zhejiang, set clear time limits.
compared to the documents issued by several provinces, for the industry's high-level pharmaceutical companies to actively report the information requirements of the failure of trust, the starting time is more than August 28, 2020, that is, the State Health Insurance Administration issued "on the establishment of pharmaceutical prices and credit evaluation system guidance" (hereinafter referred to as "guidance") point in time.
other words, there is no retrospective to the provinces that had already been convicted of the misconduct dealt with before the guidance came into force.
" is also intended to emphasize preventive guidance.
" said the above-mentioned industry insiders, according to the information disclosed by the State Health Insurance Administration, follow-up for timely, accurate and complete access to the source of information, will actively promote the overall cooperation of the department, explore with the courts, taxation, market supervision and other departments to establish exchanges and policy linkage mechanism.
However, as the National Health Insurance Administration revealed in a reporter's question, the health insurance department does not take administrative restraint measures against enterprises, enterprises are willing to only in the centralized procurement of pharmaceutical products outside the market, nor in the scope of application of the credit evaluation system, credit rating results do not extend to the field of public administration.